Stanley C. Erck has had notable fluctuations in his stock holdings during his tenure at Novavax. At his peak during the COVID-19 vaccine frenzy, his stock sales reached upwards of $12 million, showcasing serious insider trading activity. He has sold...

Stanley C. Erck has had notable fluctuations in his stock holdings during his tenure at Novavax. At his peak during the COVID-19 vaccine frenzy, his stock sales reached upwards of $12 million, showcasing serious insider trading activity. He has sold significant volumes of shares monthly, especially from 2020 to 2022, with some months showing values over $6 million. More recently, his stock sales have averaged between $200,000 to $500,000 monthly through to 2024, which indicates ongoing strategic liquidation as he prepares for retirement. His holdings demonstrate not only the ups and downs of the biotech market but also his pivotal role as a major shareholder and leader within Novavax.